Janux Therapeutics Stock Investor Sentiment
| JANX Stock | USD 45.21 1.18 2.54% |
Slightly above 67% of Janux Therapeutics' investor base is looking to short. The analysis of the overall investor sentiment regarding Janux Therapeutics suggests that many traders are alarmed. Janux Therapeutics' investing sentiment can be driven by a variety of factors including economic data, Janux Therapeutics' earnings reports, geopolitical events, and overall market trends.
Panic Vs Confidence
33
Panic | Confidence |
Today, several news technology companies offer sentiment data to assist traders in manufacturing news sentiment indicators for investment decisions. We partner with these technology firms in helping retail investors build forecasting models that use Janux Therapeutics' input sentiment indicators derived from textual data and news published on major financial information outlets and social sites. These indicators can be used to analyze time-dependent numerical information representing public perception toward Janux Therapeutics.
News SentimentBullish | Hype SentimentBearish | Insider SentimentDisposing |
Janux Historical Sentiment
Although Janux Therapeutics' investment sentiment alone cannot always predict changes in its future share prices, when combined with other fundamental and technical analysis, a better chance to time the market can be gained. Certain informational and emotional events regarding Janux, such as negative comments on social media and news outlets, may cause fear in the market and push Janux Therapeutics' investors to sell their holdings. The opposite can also be true when favorable news is released; it may translate into optimism and boost the price of Janux.
Janux |
Janux Therapeutics Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Janux Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Far too much social signal, news, headlines, and media speculation about Janux Therapeutics that are available to investors today. That information is available publicly through Janux media outlets and privately through word of mouth or via Janux internal channels. However, regardless of the origin, that massive amount of Janux data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Janux Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Janux Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Janux Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Janux Therapeutics alpha.
Janux Therapeutics Performance against Dow Jones
Price Growth (%) |
| Timeline |
1 | Disposition of 20991 shares by Avalon Ventures Xi, L.p. of Janux Therapeutics at 42.0 subject to Rule 16b-3 | 09/06/2024 |
2 | Disposition of 2182 shares by Avalon Ventures Xi, L.p. of Janux Therapeutics at 42.33 subject to Rule 16b-3 | 09/09/2024 |
3 | Disposition of 6649 shares by Avalon Ventures Xi, L.p. of Janux Therapeutics at 46.66 subject to Rule 16b-3 | 09/10/2024 |
4 | Disposition of 30613 shares by Avalon Ventures Xi, L.p. of Janux Therapeutics at 47.0 subject to Rule 16b-3 | 09/12/2024 |
5 | Disposition of 958 shares by Avalon Ventures Xi, L.p. of Janux Therapeutics at 46.24 subject to Rule 16b-3 | 09/30/2024 |
6 | Janux Therapeutics, Inc. Major Shareholder Sells 2,286,779.95 in Stock | 10/03/2024 |
7 | Disposition of 34326 shares by Avalon Ventures Xi, L.p. of Janux Therapeutics at 46.66 subject to Rule 16b-3 | 10/14/2024 |
8 | Disposition of 237 shares by Avalon Ventures Xi, L.p. of Janux Therapeutics at .8 subject to Rule 16b-3 | 10/17/2024 |
9 | Disposition of 40803 shares by Avalon Ventures Xi, L.p. of Janux Therapeutics at 47.77 subject to Rule 16b-3 | 10/25/2024 |
10 | Disposition of 11103 shares by David Campbell of Janux Therapeutics at 53.9412 subject to Rule 16b-3 | 10/28/2024 |
11 | Insider Sale President and CEO David Campbell Sells 25,000 Shares of Janux Therapeutics Inc | 10/31/2024 |
12 | Disposition of 293 shares by Avalon Ventures Xi, L.p. of Janux Therapeutics at 47.74 subject to Rule 16b-3 | 11/01/2024 |
13 | Janux Therapeutics Inc Q3 2024 Earnings EPS Misses at -0. ... | 11/06/2024 |
14 | Brokerages Set Janux Therapeutics, Inc. PT at 66.44 | 11/08/2024 |
15 | RA Capital Management, L.P. Expands Stake in Dyne Therapeutics Inc | 11/15/2024 |
16 | Leerink sets shares target on Janux Therapeutics, cites platform | 11/22/2024 |
17 | Janux Therapeutics to Host Virtual Event Discussing Updated Clinical Data in Phase 1a Dose Escalation for JANX007 in mCRPC and Doses Selected for Phase 1b Expan... | 11/25/2024 |
Additional Tools for Janux Stock Analysis
When running Janux Therapeutics' price analysis, check to measure Janux Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Janux Therapeutics is operating at the current time. Most of Janux Therapeutics' value examination focuses on studying past and present price action to predict the probability of Janux Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Janux Therapeutics' price. Additionally, you may evaluate how the addition of Janux Therapeutics to your portfolios can decrease your overall portfolio volatility.